Benitec Biopharma annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Benitec Biopharma Stock-Based Compensation Growth & History (BNTC)
Benitec Biopharma's stock-based compensation was $17.4M for fiscal 2025.
View full Benitec Biopharma company overviewBenitec Biopharma annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $17.4M | $16.6M | +1999.52% |
| 2024 | 2024-06-30 | $830,000 | $378,000 | +83.63% |
| 2023 | 2023-06-30 | $452,000 | −$418,000 | −48.05% |
| 2022 | 2022-06-30 | $870,000 | $236,000 | +37.22% |
| 2021 | 2021-06-30 | $634,000 | $397,000 | +167.51% |
| 2020 | 2020-06-30 | $237,000 | −$435,000 | −64.73% |
| 2019 | 2019-06-30 | $672,000 | — | — |
Benitec Biopharma quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $7.6M | −$152,000 | −1.96% |
| Q2 2026 | 2025-12-31 | $7.4M | $4.2M | +135.15% |
| Q1 2026 | 2025-09-30 | $5.2M | $4.7M | +1090.80% |
| Q4 2025 | 2025-06-30 | $6.1M | $5.7M | +1245.59% |
| Q3 2025 | 2025-03-31 | $7.7M | $7.6M | +3933.33% |
| Q2 2025 | 2024-12-31 | $3.1M | $3.0M | +3274.19% |
| Q1 2025 | 2024-09-30 | $435,000 | $344,000 | +378.02% |
| Q4 2024 | 2024-06-30 | $454,000 | $327,000 | +257.48% |
| Q3 2024 | 2024-03-31 | $192,000 | $121,000 | +170.42% |
| Q2 2024 | 2023-12-31 | $93,000 | $141,000 | — |
| Q1 2024 | 2023-09-30 | $91,000 | −$211,000 | −69.87% |
| Q4 2023 | 2023-06-30 | $127,000 | −$41,000 | −24.40% |
| Q3 2023 | 2023-03-31 | $71,000 | −$121,000 | −63.02% |
| Q2 2023 | 2022-12-31 | −$48,000 | −$287,000 | — |
| Q1 2023 | 2022-09-30 | $302,000 | $31,000 | +11.44% |
| Q4 2022 | 2022-06-30 | $168,000 | −$111,000 | −39.78% |
| Q3 2022 | 2022-03-31 | $192,000 | −$43,000 | −18.30% |
| Q2 2022 | 2021-12-31 | $239,000 | $157,000 | +191.46% |
| Q1 2022 | 2021-09-30 | $271,000 | $233,000 | +613.16% |
| Q4 2021 | 2021-06-30 | $279,000 | $222,000 | +389.47% |
| Q3 2021 | 2021-03-31 | $235,000 | $147,000 | +167.05% |
| Q2 2021 | 2020-12-31 | $82,000 | $45,000 | +121.62% |
| Q1 2021 | 2020-09-30 | $38,000 | −$17,000 | −30.91% |
| Q4 2020 | 2020-06-30 | $57,000 | — | — |
| Q3 2020 | 2020-03-31 | $88,000 | — | — |
| Q2 2020 | 2019-12-31 | $37,000 | — | — |
| Q1 2020 | 2019-09-30 | $55,000 | — | — |
Benitec Biopharma stock-based compensation trends
Over the last five fiscal years, Benitec Biopharma's stock-based compensation increased from $237,000 to $17.4M, a change of $17.2M. The latest reported quarter, Q3 2026, shows $7.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Benitec Biopharma source filings ↗